Background: Epidemiologic studies link maternal seafood and n-3 (ω-3) polyunsaturated fatty acid (PUFA) consumption with improved childhood cognitive development; trials show mixed results. Objective: We investigated effects of n-3 PUFA supplementation on child cognitive and visual outcomes. Methods: We systematically reviewed and meta-analyzed randomized controlled trials of n-3 PUFA supplementation in mothers or infants (age ≤2 y) and evaluated standardized measures of cognitive or visual development up to age 18 y. Of 6286 abstracts and 669 full-text articles, 38 trials with 53 intervention arms were included. Data were extracted independently in duplicate. Findings were pooled using random-effects meta-analysis across supplementation periods (maternal, preterm, term infant); we also explored subgroup analyses stratified by supplementation period. Heterogeneity was explored using I2, stratified analysis, and meta-regression. Cognitive development was assessed by Bayley Scales of Infant Development mental and psychomotor developmental indexes (MDI, PDI) and intelligence quotient (IQ); visual acuity was assessed by electrophysiological or behavioral measures. Results: The 38 trials (mothers: n = 13; preterm infants: n = 7; term infants: n = 18) included 5541 participants. When we explored effects during different periods of supplementation, n-3 PUFA supplementation improved MDI in preterm infants (3.33; 95% CI: 0.72, 5.93), without statistically significant effects on PDI or IQ in different intervention period subgroups. Visual acuity [measured as the logarithm of the minimum angle of resolution (logMAR)] was improved by supplementation in preterm (-0.08 logMAR; 95% CI: -0.14, -0.01 logMAR) and term infants (-0.08 logMAR; 95% CI: -0.11, -0.05 logMAR), with a nonsignificant trend for maternal supplementation (-0.02 logMAR; 95% CI: -0.04, 0.00 logMAR). In main analyses pooling all supplementation periods, compared with placebo, n-3 PUFA supplementation improved MDI (n = 21 trials; 0.91; 95% CI: 0.005, 1.81; P = 0.049), PDI (n = 21 trials; 1.06 higher index; 95% CI: 0.10, 2.03; P = 0.031), and visual acuity (n = 24; -0.063 logMAR; 95% CI: -0.084, -0.041 logMAR; P < 0.001) but not IQ (n = 7; 0.20; 95% CI: -1.56, 1.96, P = 0.83), although few studies assessed this endpoint. Potential publication bias was identified for MDI (Eggers P = 0.005), but not other endpoints. Significant differences in findings were not identified by world region, race, maternal education, age at outcome assessment, supplementation duration, DHA or EPA dose, DHA:AA ratio, or study quality score (P-interaction > 0.05 each). Conclusions: n-3 PUFA supplementation improves childhood psychomotor and visual development, without significant effects on global IQ later in childhood, although the latter conclusion is based on fewer studies.
Background: Epidemiologic studies link maternal seafood and n-3 (ω-3) polyunsaturated fatty acid (PUFA) consumption with improved childhood cognitive development; trials show mixed results. Objective: We investigated effects of n-3 PUFA supplementation on child cognitive and visual outcomes. Methods: We systematically reviewed and meta-analyzed randomized controlled trials of n-3 PUFA supplementation in mothers or infants (age ≤2 y) and evaluated standardized measures of cognitive or visual development up to age 18 y. Of 6286 abstracts and 669 full-text articles, 38 trials with 53 intervention arms were included. Data were extracted independently in duplicate. Findings were pooled using random-effects meta-analysis across supplementation periods (maternal, preterm, term infant); we also explored subgroup analyses stratified by supplementation period. Heterogeneity was explored using I2, stratified analysis, and meta-regression. Cognitive development was assessed by Bayley Scales of Infant Development mental and psychomotor developmental indexes (MDI, PDI) and intelligence quotient (IQ); visual acuity was assessed by electrophysiological or behavioral measures. Results: The 38 trials (mothers: n = 13; preterm infants: n = 7; term infants: n = 18) included 5541 participants. When we explored effects during different periods of supplementation, n-3 PUFA supplementation improved MDI in preterm infants (3.33; 95% CI: 0.72, 5.93), without statistically significant effects on PDI or IQ in different intervention period subgroups. Visual acuity [measured as the logarithm of the minimum angle of resolution (logMAR)] was improved by supplementation in preterm (-0.08 logMAR; 95% CI: -0.14, -0.01 logMAR) and term infants (-0.08 logMAR; 95% CI: -0.11, -0.05 logMAR), with a nonsignificant trend for maternal supplementation (-0.02 logMAR; 95% CI: -0.04, 0.00 logMAR). In main analyses pooling all supplementation periods, compared with placebo, n-3 PUFA supplementation improved MDI (n = 21 trials; 0.91; 95% CI: 0.005, 1.81; P = 0.049), PDI (n = 21 trials; 1.06 higher index; 95% CI: 0.10, 2.03; P = 0.031), and visual acuity (n = 24; -0.063 logMAR; 95% CI: -0.084, -0.041 logMAR; P < 0.001) but not IQ (n = 7; 0.20; 95% CI: -1.56, 1.96, P = 0.83), although few studies assessed this endpoint. Potential publication bias was identified for MDI (Eggers P = 0.005), but not other endpoints. Significant differences in findings were not identified by world region, race, maternal education, age at outcome assessment, supplementation duration, DHA or EPA dose, DHA:AA ratio, or study quality score (P-interaction > 0.05 each). Conclusions: n-3 PUFA supplementation improves childhood psychomotor and visual development, without significant effects on global IQ later in childhood, although the latter conclusion is based on fewer studies.
Authors: James R Drover; Dennis R Hoffman; Yolanda S Castañeda; Sarah E Morale; Sharon Garfield; Dianna H Wheaton; Eileen E Birch Journal: Early Hum Dev Date: 2011-02-03 Impact factor: 2.079
Authors: Eileen E Birch; Susan E Carlson; Dennis R Hoffman; Kathleen M Fitzgerald-Gustafson; Valeria L N Fu; James R Drover; Yolanda S Castañeda; Laura Minns; Dianna K H Wheaton; David Mundy; John Marunycz; Deborah A Diersen-Schade Journal: Am J Clin Nutr Date: 2010-02-03 Impact factor: 7.045
Authors: Dennis R Hoffman; Richard C Theuer; Yolanda S Castañeda; Dianna H Wheaton; Rain G Bosworth; Anna R O'Connor; Sarah E Morale; Lindsey E Wiedemann; Eileen E Birch Journal: J Nutr Date: 2004-09 Impact factor: 4.798
Authors: Emily Oken; Jenny S Radesky; Robert O Wright; David C Bellinger; Chitra J Amarasiriwardena; Ken P Kleinman; Howard Hu; Matthew W Gillman Journal: Am J Epidemiol Date: 2008-03-18 Impact factor: 4.897
Authors: Kelly M Boone; Andria Parrott; Joseph Rausch; Keith Owen Yeates; Mark A Klebanoff; Abigail Norris Turner; Sarah A Keim Journal: Pediatrics Date: 2020-09-04 Impact factor: 7.124
Authors: Susan B Roberts; Maria A Franceschini; Rachel E Silver; Salima F Taylor; Augusto Braima de Sa; Raimundo Có; Aliu Sonco; Amy Krauss; Amy Taetzsch; Patrick Webb; Sai Krupa Das; C-Y Chen; Beatrice L Rogers; Edward Saltzman; Pei-Yi Lin; Nina Schlossman; William Pruzensky; Carlito Balé; Kenneth Kwan Ho Chui; Paul Muentener Journal: BMJ Date: 2020-07-22
Authors: Xi Fang; Wenwu Sun; Julie Jeon; Michael Azain; Holly Kinder; Jeongyoun Ahn; Hee Cheol Chung; Ryan S Mote; Nikolay M Filipov; Qun Zhao; Srujana Rayalam; Hea Jin Park Journal: Nutrients Date: 2020-07-15 Impact factor: 5.717